ALK and lung carcinoma: Research into the role of tyrosine kinase inhibitors in EGFR gene mutations has greatly improved the prognosis of lung cancer patients with EGFR activating mutation6, 7 and with the development of molecular targeted drug research, except for EGFR mutation, many other types of targeted gene aberrations have been identified, including HER2,8BRAF,9KRAS mutations,10 and ALK rearrangement.11